Novo Nordisk announced that it will pursue regulatory approval for an oral version of its Wegovy tablet in China within the next few months, aiming to broaden its obesity‑treatment portfolio.
Regulatory Timeline and Share Reaction
Chief Executive Lars Fruergaard Jørgensen disclosed the plan during his inaugural visit to China after taking the helm in August 2023. The company’s shares on the NYSE (ticker NVO) edged up 0.09% after the briefing, reflecting modest investor optimism. Novo Nordisk hopes that a tablet format will complement the injectable Wegovy